CBST: Summary for Cubist Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 2:26am EST - Canadian Markets open in 7 hours and 4 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Cubist Pharmaceuticals Inc. (CBST)

On Feb 9: 20.58 USD

0.65 (3.26%)

MORE ON CBST

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Cubist Pharmaceuticals, Inc. (NasdaqNM:CBST) Delayed quote data

After Hours: 20.58 0.00 (0.00%) as of 4:34pm EST on 02/09/10

Last Trade:	20.58 USD
Trade Time:	Feb 9
Change:	0.65 (3.26%)
Prev Close:	19.93
Open:	20.16
Bid:	19.27 x 100
Ask:	21.78 x 200
1y Target Est:	23.14

Day's Range:	19.84 - 20.75
52wk Range:	13.81 - 22.39
Volume:	807,268
Avg Vol (3m):	623,421
Market Cap:	1.19B
P/E (ttm):	17.68
EPS (ttm):	1.16
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add CBST to Portfolio

Download Data

HEADLINES

•	Four Stock Ideas for a Muddled Market
	at Seeking Alpha (Tue, Feb 2)

•	5-Star Stocks on the Upswing
	at Motley Fool (Fri, Jan 29)

•	Today's 5-Star Movers
	at Motley Fool (Wed, Jan 27)

•	New Star Analyst Rankings for Cubist Pharmaceuticals, Inc.
	StarMine (Sat, Jan 23)

•	Cubist Misses Estimate
	Zacks.com (Fri, Jan 22)

•	Cubist Pharmaceuticals, Inc. Q4 2009 Earnings Call Transcript
	at Seeking Alpha (Thu, Jan 21)

•	Cubist 4Q profit tumbles without tax benefit
	AP (Thu, Jan 21)

•	Cubist Pharmaceuticals Fourth Quarter 2009 Earnings Call scheduled for 5:00 pm ET today
	Vcall (Thu, Jan 21)

•	CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
	EDGAR Online (Thu, Jan 21)

•	Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
	Business Wire (Thu, Jan 21)

•	Q4 2009 Cubist Pharmaceuticals, Inc. Earnings Release - Time Not Supplied
	CCBN (Thu, Jan 21)

•	A Closer Look at Cubist Pharma
	at Seeking Alpha (Thu, Jan 14)

•	Correction: Cubist Revenue Outlook
	AP (Wed, Jan 13)

More Headlines for CBST...

ANALYST

EPS Est (next year) (Dec-10) :	1.64
EPS Est (in 2 years) (Dec-11) :	1.83
Avg Rec (current)*:	2.7
PEG Ratio:	0.65

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.

Full Company Profile

Add to Portfolio

Email to a Friend

•